Roadmap

Team at CHUV, led by Dr. Michel Gilliet publish their first findings on the role of IL-26 in the inflammatory signalling pathway.

Patent on anti-IL-26 antibody received.

Signal26 Biotherapeutics was established, taking over the project.

Affinity maturation and epitope mapping works begin.

Selection of the lead monoclonal antibody (MAB) for cell line development.

Pre-clinical animal studies of the anti-IL-26 antibody commence.

Chemistry, Manufacturing, and Controls (CMC) development works start.

Initiation of toxicology studies to ensure safety and efficacy.

Clinical trials begin with healthy volunteers to assess safety and dosage.

Clinical trials with pustular psoriasis patients start to evaluate therapeutic efficacy and optimal dosing

Large-scale clinical trials commence to confirm effectiveness and monitor adverse reactions in a larger patient group.

Preparations for the commercial release of the anti-IL-26 MAB:

The anti-IL-26 monoclonal antibody is expected to become commercially available.

Continuation of research into IL-26 mechanisms and trials for other auto-inflammatory conditions such as Rheumatoid Arthritis and Irritable Bowel Disease.